GlassScriptPhysician profile
Clarita Macatula
NPI 1417313800
$1,313.04
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $639 · 2022: $71.92 · 2023: $424 · 2024: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $721.01 | 2021-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $209.30 | 2021-2024 | Arexvy |
| Exact Sciences Corporation | $119.66 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.01 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $35.05 | 2021 | |
| Pharming Healthcare, INC. | $27.88 | 2021 | |
| Novo Nordisk INC | $23.64 | 2023 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $21.37 | 2022 | |
| Lundbeck LLC | $20.51 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $17.68 | 2021 | |
| Orexo US, INC. | $17.61 | 2023 | Zubsolv |
| Acadia Pharmaceuticals INC | $17.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.15 | 2023 | Ofev |
| Shield Therapeutics INC | $15.80 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarita Macatula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.